Assessment of potential transthyretin amyloid cardiomyopathy cases in the Brazilian public health system using a machine learning model.

Autor: Zuppo Laper I; IQVIA Brazil, São Paulo, São Paulo, Brazil., Camacho-Hubner C; Pfizer Global, New York City, New York, United States of America., Vansan Ferreira R; IQVIA Brazil, São Paulo, São Paulo, Brazil., Leite Bertoli de Souza C; Pfizer Brazil, São Paulo, São Paulo, Brazil., Simões MV; Medical School of Ribeirão Preto, University of São Paulo, São Paulo, Brazil., Fernandes F; Heart Institute, University of São Paulo, São Paulo, Brazil., de Barros Correia E; Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil., de Jesus Lopes de Abreu A; IQVIA Brazil, São Paulo, São Paulo, Brazil., Silva Julian G; Pfizer Brazil, São Paulo, São Paulo, Brazil.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2024 Feb 15; Vol. 19 (2), pp. e0278738. Date of Electronic Publication: 2024 Feb 15 (Print Publication: 2024).
DOI: 10.1371/journal.pone.0278738
Abstrakt: Objectives: To identify and describe the profile of potential transthyretin cardiac amyloidosis (ATTR-CM) cases in the Brazilian public health system (SUS), using a predictive machine learning (ML) model.
Methods: This was a retrospective descriptive database study that aimed to estimate the frequency of potential ATTR-CM cases in the Brazilian public health system using a supervised ML model, from January 2015 to December 2021. To build the model, a list of ICD-10 codes and procedures potentially related with ATTR-CM was created based on literature review and validated by experts.
Results: From 2015 to 2021, the ML model classified 262 hereditary ATTR-CM (hATTR-CM) and 1,581 wild-type ATTR-CM (wtATTR-CM) potential cases. Overall, the median age of hATTR-CM and wtATTR-CM patients was 66.8 and 59.9 years, respectively. The ICD-10 codes most presented as hATTR-CM and wtATTR-CM were related to heart failure and arrythmias. Regarding the therapeutic itinerary, 13% and 5% of hATTR-CM and wtATTR-CM received treatment with tafamidis meglumine, respectively, while 0% and 29% of hATTR-CM and wtATTR-CM were referred to heart transplant.
Conclusion: Our findings may be useful to support the development of health guidelines and policies to improve diagnosis, treatment, and to cover unmet medical needs of patients with ATTR-CM in Brazil.
Competing Interests: IZL, RVF and AJLA are full-time employees at IQVIA Brazil. CCH, CLBS and GSJ are full-time employees at Pfizer Brazil. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
(Copyright: © 2024 Zuppo Laper et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje